FOCUS on MS Drug Development. Roche announced this week that the first of two pivotal phase III studies (FENhance 1 and 2) in patients with relapsing multiple sclerosis (RMS) met its primary endpoint. Fenebrutinib, an investigational BTK inhibitor, significantly reduced the annualized relapse rate compared to teriflunomide over a period of at least 96 weeks of treatment. In addition, the phase III (FENtrepid) study evaluating fenebrutinib in patients with primary progressive MS (PPMS) met its primary endpoint. These unprecedented results suggest that fenebrutinib could potentially become a best-in-disease medicine as the first high-efficacy, oral treatment for patients with RMS or PPMS.
Focus Biomolecules can supply fenebrutinib for research applications. Contact us for more information.
